NaviGate CSI (NCSI) Technology
Strategy for the AtrioVentricular Valved Stent
NCSI has developed a Mitral valved stent with very interesting attributes that has been delivered successfully Transluminally, Transapically and Transatrially in animals.
The Mitral valve was implanted TransAtrially in a First-in-Man patient in October 2015. The patient who had a 4+ MR (Mitral Regurgitation – a very debilitating heart disease) had MR reduced to zero immediately after implant. At more than 8 months post implant, the patient continues to do well and has returned to work.
NCSI has also developed a valved stent that was successfully delivered into the native Tricuspid valve Transatrially and Transluminally in animals.
Navi™ Mitral Valved Stent
In sizes: 30/36, 30/40 and 33/44
Gate™ Tricuspid Valved Stent
In sizes: 30/40, 33/44 and 36/48
Both Navi Mitral valve and Gate Tricuspid valve look similar but have different manufacturing specifications.